Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]AZD4694 PET Imaging in Alzheimer's Disease
NCT00991419Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flutafuranol in Alzheimer's disease (AD), sponsored by AstraZeneca. Primary endpoint: PET Measurements of Fibrillar Amyloid Burden at Day 7. Started Feb 2010; status: completed.
02
Drugs
flutafuranol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00991419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991419.